2009
DOI: 10.1016/j.jpain.2008.10.007
|View full text |Cite
|
Sign up to set email alerts
|

Research Gaps on Use of Opioids for Chronic Noncancer Pain: Findings From a Review of the Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
200
0
4

Year Published

2010
2010
2015
2015

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 292 publications
(209 citation statements)
references
References 129 publications
3
200
0
4
Order By: Relevance
“…In spite of there being little evidence for their specific use in the elderly [59,60], opioids are well established for the treatment of cancer pain, and increasingly used for the treatment of chronic pain. Similarly to prescribing other analgesics, the general rule for prescribing opioids in older adults is to 'start low and go slow', anticipating side-effects and treating them accordingly [61] rather than stopping treatment, and introducing different medications sequentially.…”
Section: Opioid Therapymentioning
confidence: 99%
“…In spite of there being little evidence for their specific use in the elderly [59,60], opioids are well established for the treatment of cancer pain, and increasingly used for the treatment of chronic pain. Similarly to prescribing other analgesics, the general rule for prescribing opioids in older adults is to 'start low and go slow', anticipating side-effects and treating them accordingly [61] rather than stopping treatment, and introducing different medications sequentially.…”
Section: Opioid Therapymentioning
confidence: 99%
“…10 Recommendations include urine drug testing, regular face-toface office visits to evaluate patients' response to opioids and risk of misuse, and adhering to a pre-defined refill schedule (i.e., restricting refills of opioids prior to expiration of the previous prescription). Although strong evidence to support these recommendations is lacking, 11,12 experts endorse their role especially for patients at high risk of opioid misuse. [7][8][9]13 Several patient characteristics have been associated with an increased risk of opioid misuse in observational studies.…”
Section: Introductionmentioning
confidence: 99%
“…Despite these limitations, these studies provide sufficient evidence of efficacy, that is, lower short-term pain scores than placebo, to satisfy regulators and obtain market approval. 40 The recent approval of Zohydro Ò ER, an extendedrelease analgesic containing hydrocodone made by Zogenix, is a prime example of this phenomenon. This product was approved for ''moderate-to-severe chronic pain'' in 2014 despite having no features to deter abuse and an outright backlash from lawmakers, industry groups, medical professionals, and US Food and Drug Administration panel advisors alike.…”
Section: Benefits Of Therapymentioning
confidence: 99%